We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
Read MoreHide Full Article
Clinical-stage biopharmaceutical company, Fate Therapeutics, Inc. (FATE - Free Report) , announced that the FDA has cleared its Investigational New Drug (IND) application for pipeline candidate, FT819.
FT819 is an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. It has been derived from a clonal master induced pluripotent stem cell (iPSC) line.
Fate plans to initiate a study on FT819 for the treatment of patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).
The multi-center phase I study of FT819 will determine the maximum tolerated dose of FT819. The study will assess its safety and clinical activity in up to 297 adult patients across these three types of B-cell malignancies.
The company will enroll independently for each indication. The candidate will be evaluated in three dose-escalating treatment regimens — Regimen A as a single dose of FT819, Regimen B as a single dose of FT819 with IL-2 cytokine support and Regimen C as three fractionated doses of FT819. Additionally, dose-expansion cohorts of up to 15 patients may be enrolled to further evaluate the clinical activity of FT819 for each indication and regimen.
We note that Fate’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and target tumor-associated antigens with CARs. The immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a phase II study for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders.
To develop its pipeline, Fate has entered into collaborations with other companies.
The company has entered into a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates.
In April 2020, Fate entered into a collaboration and option agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ - Free Report) , to develop iPSC-derived CAR NK and CAR T-cell product candidates for the treatment of cancer. Shares surged on the collaboration news.
The company’s shares have soared 85.8% so far this year compared with the industry’s growth of 12.3%
Cellular immunotherapies promise huge potential. Hence, companies like Gilead Sciences, Inc. (GILD - Free Report) and Bristol-Myers Squibb Company (BMY - Free Report) are currently focusing on the development of cellular immunotherapies for the treatment of cancer.
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
Clinical-stage biopharmaceutical company, Fate Therapeutics, Inc. (FATE - Free Report) , announced that the FDA has cleared its Investigational New Drug (IND) application for pipeline candidate, FT819.
FT819 is an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. It has been derived from a clonal master induced pluripotent stem cell (iPSC) line.
Fate plans to initiate a study on FT819 for the treatment of patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).
The multi-center phase I study of FT819 will determine the maximum tolerated dose of FT819. The study will assess its safety and clinical activity in up to 297 adult patients across these three types of B-cell malignancies.
The company will enroll independently for each indication. The candidate will be evaluated in three dose-escalating treatment regimens — Regimen A as a single dose of FT819, Regimen B as a single dose of FT819 with IL-2 cytokine support and Regimen C as three fractionated doses of FT819. Additionally, dose-expansion cohorts of up to 15 patients may be enrolled to further evaluate the clinical activity of FT819 for each indication and regimen.
We note that Fate’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and target tumor-associated antigens with CARs. The immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a phase II study for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders.
To develop its pipeline, Fate has entered into collaborations with other companies.
The company has entered into a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates.
In April 2020, Fate entered into a collaboration and option agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ - Free Report) , to develop iPSC-derived CAR NK and CAR T-cell product candidates for the treatment of cancer. Shares surged on the collaboration news.
The company’s shares have soared 85.8% so far this year compared with the industry’s growth of 12.3%
Cellular immunotherapies promise huge potential. Hence, companies like Gilead Sciences, Inc. (GILD - Free Report) and Bristol-Myers Squibb Company (BMY - Free Report) are currently focusing on the development of cellular immunotherapies for the treatment of cancer.
Fate currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>